Melanie Bissessor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Melanie Bissessor has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Kincaid Fairley
Central Clinical School, Monash University, Melbourne, Victoria, Australia
11 shared publications - Catriona S. Bradshaw
Melbourne Sexual Health Centre, Alfred Health
6 shared publications - Eric Pui Fung Chow
AMelbourne Sexual Health Centre, Bayside Health, Melbourne, Vic, Australia.
5 shared publications - Jane Simone Hocking
Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia
5 shared publications - Marcus Y. Chen
Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia
5 shared publications - Jason J. Ong
AMelbourne Sexual Health Centre, Bayside Health, Melbourne, Vic, Australia
4 shared publications
Latest Publications
- Open Access
- 25 March 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (7) , 3935
Improving Access to Sexual Health Services in General Practice Using a Hub-and-Spoke Model: A Mixed-Methods Evaluation
Improving access to sexual health services is critical in light of rising sexually transmitted infections (STIs). We evaluated a hub-and-spoke model for improving access to sexual health services in three general practices in Victoria, Australia. The primary outcome was the impact on HIV and STI (chlamydia, gonorrhoea, syphilis) testing. Segmented linear regression analysis was conducted to examine the trends in the total HIV/STI tests pre- (from January 2019 to June 2020) and post-implementation (from July 2020 to July 2021). We evaluated the feasibility and acceptability of integrating this model into the general practices using semi-structured individual interviews. There was a statistically significant rise in testing for HIV and STIs in all general practices: post-implementation, there was an increase of an average of 11.2 chlamydia tests per month (p = 0.026), 10.5 gonorrhoea tests per month (p = 0.001), 4.3 syphilis tests per month (p = 0.010), and 5.6 HIV tests per month (p = 0.010). Participants reported increases in knowledge level and confidence in offering STI testing and managing a greater variety of sexual health cases. This study demonstrates the feasibility of implementing a hub-and-spoke model to enable GPs to deliver sexual health care with support from a sexual health specialist service.
- 25 March 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (7) , 3935
Open AccessImproving Access to Sexual Health Services in General Practice Using a Hub-and-Spoke Model: A Mixed-Methods Evaluation
Improving access to sexual health services is critical in light of rising sexually transmitted infections (STIs). We evaluated a hub-and-spoke model for improving access to sexual health services in three general practices in Victoria, Australia. The primary outcome was the impact on HIV and STI (chlamydia, gonorrhoea, syphilis) testing. Segmented linear regression analysis was conducted to examine the trends in the total HIV/STI tests pre- (from January 2019 to June 2020) and post-implementation (from July 2020 to July 2021). We evaluated the feasibility and acceptability of integrating this model into the general practices using semi-structured individual interviews. There was a statistically significant rise in testing for HIV and STIs in all general practices: post-implementation, there was an increase of an average of 11.2 chlamydia tests per month (p = 0.026), 10.5 gonorrhoea tests per month (p = 0.001), 4.3 syphilis tests per month (p = 0.010), and 5.6 HIV tests per month (p = 0.010). Participants reported increases in knowledge level and confidence in offering STI testing and managing a greater variety of sexual health cases. This study demonstrates the feasibility of implementing a hub-and-spoke model to enable GPs to deliver sexual health care with support from a sexual health specialist service.
- Open Access
- 16 February 2022
- Published by MDPI AG in Preprints.org
Improving Access to Sexual Health Services in General Practice Using a Hub-and-Spoke Model: A Mixed-Methods Evaluation
Improving access to sexual health services is critical in light of rising sexually transmitted infections (STIs). We evaluated a Hub and Spoke model for improving access to sexual health services in three general practices in Victoria, Australia. The primary outcome was the impact on HIV and STI (chlamydia, gonorrhoea, syphilis) testing. Segmented linear regression analysis was conducted to examine the trends in the total HIV/STI tests before (from January 2019 to June 2020) and post-implementation (from July 2020 to July 2021). We evaluated the feasibility and acceptability of integrating this model into the general practices using semi-structured individual interviews. There was a statistically significant rise in testing for HIV and STIs in all general practices: post-implementation, there was an increase of an average of 11.2 chlamydia tests per month (p=0.026), 10.5 gonorrhoea tests per month (p=0.001), 4.3 syphilis tests per month (p=0.010), and 5.6 HIV tests per month (p=0.010). Participants reported increases in knowledge level and confidence in offering STI testing and managing more variety of sexual health cases. This study demonstrated the feasibility of implementing a hub and spoke model to enable GPs to deliver sexual health care with support from a sexual health specialist service.
- 16 February 2022
- Published by MDPI AG in Preprints.org
Open AccessImproving Access to Sexual Health Services in General Practice Using a Hub-and-Spoke Model: A Mixed-Methods Evaluation
Improving access to sexual health services is critical in light of rising sexually transmitted infections (STIs). We evaluated a Hub and Spoke model for improving access to sexual health services in three general practices in Victoria, Australia. The primary outcome was the impact on HIV and STI (chlamydia, gonorrhoea, syphilis) testing. Segmented linear regression analysis was conducted to examine the trends in the total HIV/STI tests before (from January 2019 to June 2020) and post-implementation (from July 2020 to July 2021). We evaluated the feasibility and acceptability of integrating this model into the general practices using semi-structured individual interviews. There was a statistically significant rise in testing for HIV and STIs in all general practices: post-implementation, there was an increase of an average of 11.2 chlamydia tests per month (p=0.026), 10.5 gonorrhoea tests per month (p=0.001), 4.3 syphilis tests per month (p=0.010), and 5.6 HIV tests per month (p=0.010). Participants reported increases in knowledge level and confidence in offering STI testing and managing more variety of sexual health cases. This study demonstrated the feasibility of implementing a hub and spoke model to enable GPs to deliver sexual health care with support from a sexual health specialist service.
- 29 March 2021
- Published by BMJ in Sexually Transmitted Infections
- Vol. 98 (3) , 161-165
Timing of primary syphilis treatment and impact on the development of treponemal antibodies: a cross-sectional clinic-based study
Background: Serology is negative in a proportion of primary syphilis cases where Treponema pallidum PCR testing is positive. We aimed to identify discordant, T. pallidum PCR-positive, serology-negative primary syphilis cases and any clinical or laboratory factors associated with failure to subsequently seroconvert.Methods: Serodiscordant primary syphilis cases that were T. pallidum PCR-positive and serology-negative (including rapid plasma reagin, T. pallidum particle agglutination, T. pallidum enzyme immunoassay or T. pallidum chemiluminescence assay) were identified from the Melbourne Sexual Health Centre electronic records between April 2011 and December 2019. Clinical and laboratory associations were examined.Results: There were 814 primary syphilis cases in the study period and 38 (4.7%) were serodiscordant, 35 in men who have sex with men. Thirty-two had follow-up serology performed a median of 24 days later, of which 16 (50%) seroconverted, mostly (81%) within 6 weeks. Failure to seroconvert was significantly associated with treatment on day 1. Of the 12 cases treated on day 1, 10 (83%) failed to seroconvert compared with 6 of 20 (30%) among those who were treated after day 1.Discussion: Earlier treatment of primary syphilis can prevent the development of serological markers. T. pallidum PCR can identify primary syphilis lesions before the development of serological markers and improve diagnosis of early primary syphilis lesions. Serology alone will miss a proportion of primary syphilis infections and should be repeated if a diagnosis of syphilis is being considered.
- 29 March 2021
- Published by BMJ in Sexually Transmitted Infections
- Vol. 98 (3) , 161-165
Timing of primary syphilis treatment and impact on the development of treponemal antibodies: a cross-sectional clinic-based study
Background: Serology is negative in a proportion of primary syphilis cases where Treponema pallidum PCR testing is positive. We aimed to identify discordant, T. pallidum PCR-positive, serology-negative primary syphilis cases and any clinical or laboratory factors associated with failure to subsequently seroconvert.Methods: Serodiscordant primary syphilis cases that were T. pallidum PCR-positive and serology-negative (including rapid plasma reagin, T. pallidum particle agglutination, T. pallidum enzyme immunoassay or T. pallidum chemiluminescence assay) were identified from the Melbourne Sexual Health Centre electronic records between April 2011 and December 2019. Clinical and laboratory associations were examined.Results: There were 814 primary syphilis cases in the study period and 38 (4.7%) were serodiscordant, 35 in men who have sex with men. Thirty-two had follow-up serology performed a median of 24 days later, of which 16 (50%) seroconverted, mostly (81%) within 6 weeks. Failure to seroconvert was significantly associated with treatment on day 1. Of the 12 cases treated on day 1, 10 (83%) failed to seroconvert compared with 6 of 20 (30%) among those who were treated after day 1.Discussion: Earlier treatment of primary syphilis can prevent the development of serological markers. T. pallidum PCR can identify primary syphilis lesions before the development of serological markers and improve diagnosis of early primary syphilis lesions. Serology alone will miss a proportion of primary syphilis infections and should be repeated if a diagnosis of syphilis is being considered.
- 1 February 2021
- Published by BMJ in Sexually Transmitted Infections
- Vol. 98 (2) , 139-141
Culture obtained from urethral swab of asymptomatic men who screen positive forNeisseria gonorrhoeaeby urine nucleic acid amplification testing
Background: In a previous study of men attending Melbourne Sexual Health Centre who hadNeisseria gonorrhoeaedetected by urine Aptima Combo 2 (AC2) testing, 11% were asymptomatic. This study aimed to determine whetherN. gonorrhoeaecan be cultured from asymptomatic men screening positive forN. gonorrhoeaeby nucleic acid amplification testing (NAAT) of urine.Methods: Between 1 July 2017 and 31 March 2019, all men attending Melbourne Sexual Health Centre were tested forN. gonorrhoeaeby AC2 testing of urine whether urethral symptoms were reported or not. NAAT-positive men were recalled and a urethral swab performed for gonococcal culture using modified Thayer-Martin media with determination of minimum inhibitory concentrations (MICs) by agar dilution.Results: There were 1001 cases (860 individuals) positive forN. gonorrhoeaeby urine AC2: 892 (89%) reported urethral symptoms; 109 (11%) did not. Twenty-five asymptomatic cases were excluded because of antibiotic use at or following screening. Of the remaining 84 asymptomatic men, 41 (49%) had a urethral swab performed a median of 5 days after screening. Twenty-one men had urethral discharge at the return visit, 11 of whom reported the discharge at the return visit. Of the 41 men who were swabbed, 31 (76%; 95% CI 60% to 88%) were culture positive forN. gonorrhoeae. Among the 21 men who subsequently developed discharge, 19 (90%; 95% CI 70% to 99%) were culture positive. Among the 20 men who remained asymptomatic, 12 (60%; 95% CI 36% to 81%) were culture positive. MIC profiles were obtained from all isolates.Conclusions: Gonorrhoea was isolated in most but not all asymptomatic men screening positive forN. gonorrhoeaeby urine NAAT. Clinicians should consider performing urethral culture in such men to ensure optimal surveillance for antimicrobial resistance. Isolation ofN. gonorrhoeaeby culture in men without discharge indicates these are true infections with viable organisms.
- 1 February 2021
- Published by BMJ in Sexually Transmitted Infections
- Vol. 98 (2) , 139-141
Culture obtained from urethral swab of asymptomatic men who screen positive forNeisseria gonorrhoeaeby urine nucleic acid amplification testing
Background: In a previous study of men attending Melbourne Sexual Health Centre who hadNeisseria gonorrhoeaedetected by urine Aptima Combo 2 (AC2) testing, 11% were asymptomatic. This study aimed to determine whetherN. gonorrhoeaecan be cultured from asymptomatic men screening positive forN. gonorrhoeaeby nucleic acid amplification testing (NAAT) of urine.Methods: Between 1 July 2017 and 31 March 2019, all men attending Melbourne Sexual Health Centre were tested forN. gonorrhoeaeby AC2 testing of urine whether urethral symptoms were reported or not. NAAT-positive men were recalled and a urethral swab performed for gonococcal culture using modified Thayer-Martin media with determination of minimum inhibitory concentrations (MICs) by agar dilution.Results: There were 1001 cases (860 individuals) positive forN. gonorrhoeaeby urine AC2: 892 (89%) reported urethral symptoms; 109 (11%) did not. Twenty-five asymptomatic cases were excluded because of antibiotic use at or following screening. Of the remaining 84 asymptomatic men, 41 (49%) had a urethral swab performed a median of 5 days after screening. Twenty-one men had urethral discharge at the return visit, 11 of whom reported the discharge at the return visit. Of the 41 men who were swabbed, 31 (76%; 95% CI 60% to 88%) were culture positive forN. gonorrhoeae. Among the 21 men who subsequently developed discharge, 19 (90%; 95% CI 70% to 99%) were culture positive. Among the 20 men who remained asymptomatic, 12 (60%; 95% CI 36% to 81%) were culture positive. MIC profiles were obtained from all isolates.Conclusions: Gonorrhoea was isolated in most but not all asymptomatic men screening positive forN. gonorrhoeaeby urine NAAT. Clinicians should consider performing urethral culture in such men to ensure optimal surveillance for antimicrobial resistance. Isolation ofN. gonorrhoeaeby culture in men without discharge indicates these are true infections with viable organisms.
- 1 April 2017
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 44 (4) , 245-248
Treatment Outcomes for Rectal Lymphogranuloma Venereum in Men Who Have Sex with Men Using Doxycycline, Azithromycin, or Both: A Review of Clinical Cases
Background: Treatment for rectal lymphogranuloma venereum where doxycycline 100 mg twice daily for 21 days was used—either alone or together with azithromycin 1 g single dose—resulted in microbiological cure of 97%. These data support doxycycline 100 mg twice daily for 21 days as the preferred treatment for rectal lymphogranuloma venereum.
- 1 April 2017
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 44 (4) , 245-248
Treatment Outcomes for Rectal Lymphogranuloma Venereum in Men Who Have Sex with Men Using Doxycycline, Azithromycin, or Both: A Review of Clinical Cases
Background: Treatment for rectal lymphogranuloma venereum where doxycycline 100 mg twice daily for 21 days was used—either alone or together with azithromycin 1 g single dose—resulted in microbiological cure of 97%. These data support doxycycline 100 mg twice daily for 21 days as the preferred treatment for rectal lymphogranuloma venereum.
- 1 March 2016
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 22 (3) , 260-265
The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men
- 1 March 2016
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 22 (3) , 260-265
The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men
- Open Access
- 1 November 2015
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 53 (11) , 3624-3626
Detection of Neisseria gonorrhoeae Isolates from Tonsils and Posterior Oropharynx
We examined the factors influencing gonorrhea detection at the pharynx. One hundred men infected with Neisseria gonorrhoeae were swabbed from the tonsils and posterior oropharynx. N. gonorrhoeae was reisolated from the tonsils and posterior oropharynx in 62% and 52%, respectively ( P = 0.041). Culture positivity was greater with higher gonococcal DNA loads at the tonsils ( P = 0.001) and oropharynx ( P < 0.001). N. gonorrhoeae can be cultured from the tonsils and posterior oropharynx with greater isolation rates where gonococcal loads are higher.
- 1 November 2015
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 53 (11) , 3624-3626
Open AccessDetection of Neisseria gonorrhoeae Isolates from Tonsils and Posterior Oropharynx
We examined the factors influencing gonorrhea detection at the pharynx. One hundred men infected with Neisseria gonorrhoeae were swabbed from the tonsils and posterior oropharynx. N. gonorrhoeae was reisolated from the tonsils and posterior oropharynx in 62% and 52%, respectively ( P = 0.041). Culture positivity was greater with higher gonococcal DNA loads at the tonsils ( P = 0.001) and oropharynx ( P < 0.001). N. gonorrhoeae can be cultured from the tonsils and posterior oropharynx with greater isolation rates where gonococcal loads are higher.
- Open Access
- 23 December 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (8) , 1228-1236
Macrolide Resistance and Azithromycin Failure in a Mycoplasma genitalium-Infected Cohort and Response of Azithromycin Failures to Alternative Antibiotic Regimens
Background. Our aim was to determine the efficacy of 1 g azithromycin and alternative antibiotic regimens in a prospective cohort of Mycoplasma genitalium–infected participants, and factors associated with azithromycin failure. Methods. Consecutive eligible M. genitalium–infected men and women attending the Melbourne Sexual Health Centre between July 2012 and June 2013 were treated with 1 g of azithromycin and retested by polymerase chain reaction (PCR) on days 14 and 28. Cure was defined as PCR negative on day 28. Cases failing azithromycin were treated with moxifloxacin, and those failing moxifloxacin were treated with pristinamycin. Pre- and posttreatment samples were assessed for macrolide resistance mutations (MRMs) by high-resolution melt analysis. Mycoplasma genitalium samples from cases failing moxifloxacin were sequenced for fluoroquinolone resistance mutations. Multivariable analysis was used to examine associations with azithromycin failure. Results. Of 155 participants treated with 1 g azithromycin, 95 (61% [95% confidence interval {CI}, 53%–69%]) were cured. Pretreatment MRM was detected in 56 (36% [95% CI, 28%–43%]) participants, and strongly associated with treatment failure (87% [95% CI, 76%–94%]; adjusted odds ratio, 47.0 [95% CI, 17.1–129.0]). All 11 participants who had MRM detected in posttreatment samples failed azithromycin. Moxifloxacin was effective in 53(88% [95% CI, 78%–94%]) of 60 cases failing azithromycin; all failures had gyrA and parC mutations detected in pretreatment samples. Six of 7 patients failing moxifloxacin treatment received pristinamycin, and all were PCR negative 28 days after pristinamycin treatment. Conclusions. We report a high azithromycin failure rate (39%) in an M. genitalium–infected cohort in association with high levels of pretreatment macrolide resistance. Moxifloxacin failure occurred in 12% of patients who received moxifloxacin; all had pretreatment fluoroquinolone mutations detected. Pristinamycin was highly effective in treating macrolide- and quinolone-resistant strains.
- 23 December 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (8) , 1228-1236
Open AccessMacrolide Resistance and Azithromycin Failure in a Mycoplasma genitalium-Infected Cohort and Response of Azithromycin Failures to Alternative Antibiotic Regimens
Background. Our aim was to determine the efficacy of 1 g azithromycin and alternative antibiotic regimens in a prospective cohort of Mycoplasma genitalium–infected participants, and factors associated with azithromycin failure. Methods. Consecutive eligible M. genitalium–infected men and women attending the Melbourne Sexual Health Centre between July 2012 and June 2013 were treated with 1 g of azithromycin and retested by polymerase chain reaction (PCR) on days 14 and 28. Cure was defined as PCR negative on day 28. Cases failing azithromycin were treated with moxifloxacin, and those failing moxifloxacin were treated with pristinamycin. Pre- and posttreatment samples were assessed for macrolide resistance mutations (MRMs) by high-resolution melt analysis. Mycoplasma genitalium samples from cases failing moxifloxacin were sequenced for fluoroquinolone resistance mutations. Multivariable analysis was used to examine associations with azithromycin failure. Results. Of 155 participants treated with 1 g azithromycin, 95 (61% [95% confidence interval {CI}, 53%–69%]) were cured. Pretreatment MRM was detected in 56 (36% [95% CI, 28%–43%]) participants, and strongly associated with treatment failure (87% [95% CI, 76%–94%]; adjusted odds ratio, 47.0 [95% CI, 17.1–129.0]). All 11 participants who had MRM detected in posttreatment samples failed azithromycin. Moxifloxacin was effective in 53(88% [95% CI, 78%–94%]) of 60 cases failing azithromycin; all failures had gyrA and parC mutations detected in pretreatment samples. Six of 7 patients failing moxifloxacin treatment received pristinamycin, and all were PCR negative 28 days after pristinamycin treatment. Conclusions. We report a high azithromycin failure rate (39%) in an M. genitalium–infected cohort in association with high levels of pretreatment macrolide resistance. Moxifloxacin failure occurred in 12% of patients who received moxifloxacin; all had pretreatment fluoroquinolone mutations detected. Pristinamycin was highly effective in treating macrolide- and quinolone-resistant strains.
- Open Access
- 3 November 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (4) , 557-563
Persistence of Neisseria gonorrhoeae DNA Following Treatment for Pharyngeal and Rectal Gonorrhea Is Influenced by Antibiotic Susceptibility and Reinfection
Authors examined persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea; N. gonorrhoeae DNA persisted in 8% of men 14 days after treatment. Persistence was associated with elevated ceftriaxone and azithromycin MICs and may also reflect reinfection. Background. To guide interpretation of gonorrhea tests of cure using nucleic acid amplification testing, this study examined the persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea. Methods. Men who had sex with men diagnosed with pharyngeal or rectal gonorrhea underwent swabbing from the pharynx or rectum 7 and 14 days following treatment. Repeat testing for N. gonorrhoeae was undertaken using real-time polymerase chain reaction (PCR) assays targeting the opa gene and porA pseudogene. Results. One hundred pharyngeal and 100 rectal gonorrhea infections in 190 men were included. For pharyngeal gonorrhea, positivity of N. gonorrhoeae DNA on both PCR assays was present at days 7 or 14 in 13% (95% confidence interval [CI], 6.4%–19.6%) and 8% (95% CI, 2.7%–13.3%), respectively. For rectal gonorrhea, DNA positivity was present in 6% (95% CI, 1.4%–10.7%) and 8% (95% CI, 2.7%–13.3%), respectively. Among 200 baseline pharyngeal and rectal isolates, there were 10 with ceftriaxone minimum inhibitory concentration (MIC) ≥0.06 mg/L and azithromycin MIC ≥0.5 mg/L, of which 3 (30%) had DNA detected at day 14; among the 190 isolates with lower ceftriaxone and azithromycin MICs, only 13 (7%) had persistent DNA (odds ratio, 5.8 [95% CI, 1.3–25.4]; P = .019). One man initially infected with N. gonorrhoeae multiantigen sequence type 2400 had type 4244 infection at day 14, indicating reinfection. Conclusions. Pharyngeal and rectal gonorrhea DNA persisted in 8% of men 14 days after treatment. Persistence was associated with elevated ceftriaxone and azithromycin MICs. Persistence can also reflect reinfection.
- 3 November 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (4) , 557-563
Open AccessPersistence of Neisseria gonorrhoeae DNA Following Treatment for Pharyngeal and Rectal Gonorrhea Is Influenced by Antibiotic Susceptibility and Reinfection
Authors examined persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea; N. gonorrhoeae DNA persisted in 8% of men 14 days after treatment. Persistence was associated with elevated ceftriaxone and azithromycin MICs and may also reflect reinfection. Background. To guide interpretation of gonorrhea tests of cure using nucleic acid amplification testing, this study examined the persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea. Methods. Men who had sex with men diagnosed with pharyngeal or rectal gonorrhea underwent swabbing from the pharynx or rectum 7 and 14 days following treatment. Repeat testing for N. gonorrhoeae was undertaken using real-time polymerase chain reaction (PCR) assays targeting the opa gene and porA pseudogene. Results. One hundred pharyngeal and 100 rectal gonorrhea infections in 190 men were included. For pharyngeal gonorrhea, positivity of N. gonorrhoeae DNA on both PCR assays was present at days 7 or 14 in 13% (95% confidence interval [CI], 6.4%–19.6%) and 8% (95% CI, 2.7%–13.3%), respectively. For rectal gonorrhea, DNA positivity was present in 6% (95% CI, 1.4%–10.7%) and 8% (95% CI, 2.7%–13.3%), respectively. Among 200 baseline pharyngeal and rectal isolates, there were 10 with ceftriaxone minimum inhibitory concentration (MIC) ≥0.06 mg/L and azithromycin MIC ≥0.5 mg/L, of which 3 (30%) had DNA detected at day 14; among the 190 isolates with lower ceftriaxone and azithromycin MICs, only 13 (7%) had persistent DNA (odds ratio, 5.8 [95% CI, 1.3–25.4]; P = .019). One man initially infected with N. gonorrhoeae multiantigen sequence type 2400 had type 4244 infection at day 14, indicating reinfection. Conclusions. Pharyngeal and rectal gonorrhea DNA persisted in 8% of men 14 days after treatment. Persistence was associated with elevated ceftriaxone and azithromycin MICs. Persistence can also reflect reinfection.
- Open Access
- 7 June 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (1) , 57-58
Use of a Computer Alert Increases Detection of Early, Asymptomatic Syphilis Among Higher-Risk Men Who Have Sex With Men
Our study assessed the impact of a computer alert that reminded clinicians to test men who were at higher risk for syphilis on the rate of syphilis testing and diagnoses. The percentage of high-risk men who have sex with men who were tested for syphilis increased from 77% to 89% (P > .001), and the percentage of such men with asymptomatic syphilis increased from 16% to 53% (P = .001).
- 7 June 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (1) , 57-58
Open AccessUse of a Computer Alert Increases Detection of Early, Asymptomatic Syphilis Among Higher-Risk Men Who Have Sex With Men
Our study assessed the impact of a computer alert that reminded clinicians to test men who were at higher risk for syphilis on the rate of syphilis testing and diagnoses. The percentage of high-risk men who have sex with men who were tested for syphilis increased from 77% to 89% (P > .001), and the percentage of such men with asymptomatic syphilis increased from 16% to 53% (P = .001).